Literature DB >> 17426093

Impact of fasting glycemia on short-term prognosis after acute myocardial infarction.

Bruno Vergès1, Marianne Zeller, Gilles Dentan, Jean-Claude Beer, Yves Laurent, Luc Janin-Manificat, Hamid Makki, Jean Eric Wolf, Yves Cottin.   

Abstract

OBJECTIVE: The prognosis of patients with acute myocardial infarction (MI), according to the new criteria for impaired fasting glucose (IFG) (FG 100-126 mg/dl), has not been evaluated. RESEARCH DESIGN AND METHODS: A total of 2353 patients with acute MI and surviving at d 5 after admission were analyzed for short-term morbidity and mortality. FG was obtained at d 4 and 5. Patients were classified as diabetes mellitus (known diabetes or FG > or = 126 mg/dl), high IFG (110 < or = FG < 126 mg/dl), low IFG (100 < or = FG < 110 mg/dl), and normal fasting glucose (NFG) (FG < 100 mg/dl).
RESULTS: Among the 2353 patients, 968 (41%) had diabetes mellitus, 262 (11%) had high IFG, 332 (14%) had low IFG, and 791 (34%) had NFG. Compared with NFG patients, 30-d cardiovascular mortality was increased in high but not low IFG subjects. In-hospital heart failure was increased in high IFG subjects (42 vs. 20% for NFG, P < 0.0001) but not low IFG subjects (21 vs. 20%). High IFG, but not low IFG, was an independent factor associated with 30-d cardiovascular mortality [odds ratio 2.33 (1.55-3.47)] and in-hospital heart failure [odds ratio 1.70 (1.36-2.07)]. The optimal threshold levels of FG on the receiver-operating characteristic curves were 114 and 112 mg/dl to predict mortality and in-hospital heart failure, respectively.
CONCLUSION: The present study, based on a nonselected cohort of MI patients, underscores the high prevalence of IFG (25%) and highlights the clinical relevance of 110 mg/dl, but not 100 mg/dl, as a cutoff value to define the risk for worse outcome.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17426093     DOI: 10.1210/jc.2006-2584

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

Review 1.  An overview of glycemic control in the coronary care unit with recommendations for clinical management.

Authors:  Mikhail Kosiborod; Prakash Deedwania
Journal:  J Diabetes Sci Technol       Date:  2009-11-01

2.  In-hospital complications after invasive strategy for the management of Non STEMI: women fare as well as men.

Authors:  Caroline Berthillot; Dominique Stephan; Michel Chauvin; Gerald Roul
Journal:  BMC Cardiovasc Disord       Date:  2010-06-24       Impact factor: 2.298

3.  Admission glucose, fasting glucose, HbA1c levels and the SYNTAX score in non-diabetic patients undergoing coronary angiography.

Authors:  Yaron Arbel; Margalit Zlotnik; Amir Halkin; Ofer Havakuk; Shlomo Berliner; Itzhak Herz; Itay Rabinovich; Gad Keren; Shmuel Bazan; Ariel Finkelstein; Shmuel Banai
Journal:  Clin Res Cardiol       Date:  2013-11-24       Impact factor: 5.460

Review 4.  Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes.

Authors:  Mitchel Tate; Aaron Chong; Emma Robinson; Brian D Green; David J Grieve
Journal:  Br J Pharmacol       Date:  2014-12-01       Impact factor: 8.739

5.  Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice.

Authors:  Meghan Sauvé; Kiwon Ban; M Abdul Momen; Yu-Qing Zhou; R Mark Henkelman; Mansoor Husain; Daniel J Drucker
Journal:  Diabetes       Date:  2010-01-22       Impact factor: 9.461

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.